Posts by Mourabit Halima

Editor’s Note: The 8th Conference on Oncology Precision Medicine and the 11th Conference on Individualized Therapy for Breast Cancer were recently held in Beijing, jointly organized by the Beijing Breast…

Editor’s Note: Endocrine resistance is one of the major challenges in the treatment of HR+/HER2- breast cancer. At the 8th Conference on Oncology Precision Medicine and the 11th Conference on…

Editor’s Note: The 2025 Summer Breast Cancer Forum · Northern Salon was held in Qingdao, Shandong, from August 8–10. Upholding the spirit of “learning and innovation” and the tradition of…

Editor’s Note: For patients with intermediate-risk hormone receptor–positive early breast cancer (HR+ EBC), should adjuvant therapy prioritize chemotherapy plus an aromatase inhibitor (AI), or an AI combined with a CDK4/6…

This September, the city of Jinan welcomed one of China’s most prestigious academic events in oncology. The 28th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO 2025) officially opened on the morning of September 11th, gathering experts, clinicians, researchers, and industry representatives from across the country. Multiple academicians and internationally renowned oncologists attended the ceremony to discuss new progress in cancer prevention and treatment under the theme “Standardized Treatment, Innovation-Driven Leadership”—together charting a new global blueprint for the fight against cancer.

For patients with hormone receptor–positive (HR+) advanced breast cancer who progress after treatment with CDK4/6 inhibitors, should clinicians choose antibody–drug conjugates (ADCs) or a combination of targeted therapy plus endocrine therapy (ET)? At the 2025 Summer Breast Cancer Forum · Northern Salon, the “Debate” session addressed this very question. Professor Ning Xie of Hunan Cancer Hospital and Professor Lingzhi Xu of the Second Affiliated Hospital of Dalian Medical University presented evidence-based arguments for ADCs and for targeted therapy + ET, respectively. In this Oncology Frontier feature, they further elaborate on their viewpoints.